US Bancorp
CRNX

US Bancorp’s Crinetics Pharmaceuticals CRNX Stock Holding History

US Bancorp’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$261K Sell
6,967
-94
-1% -$3.49K ﹤0.01% 1961
2026
Q1 		$256K Buy
7,061
+1,550
+28% +$69.2K ﹤0.01% 1877
2025
Q4 		$257K Buy
5,511
+405
+8% +$18K ﹤0.01% 1902
2025
Q3 		$213K Buy
5,106
+202
+4% +$6.46K ﹤0.01% 1967
2025
Q2 		$141K Buy
4,904
+171
+4% +$5.28K ﹤0.01% 2243
2025
Q1 		$159K Sell
4,733
-1,579
-25% -$59K ﹤0.01% 2141
2024
Q4 		$323K Sell
6,312
-5,176
-45% -$290K ﹤0.01% 1748
2024
Q3 		$587K Buy
11,488
+373
+3% +$19.2K ﹤0.01% 1421
2024
Q2 		$498K Buy
11,115
+6,952
+167% +$321K ﹤0.01% 1493
2024
Q1 		$195K Buy
4,163
+3,958
+1,931% +$155K ﹤0.01% 2024
2023
Q4 		$7.29K Sell
205
-8,786
-98% -$269K ﹤0.01% 3413
2023
Q3 		$267K Buy
8,991
+8,928
+14,171% +$184K ﹤0.01% 1700
2023
Q2 		$1.14K Sell
63
-87
-58% -$1.74K ﹤0.01% 3793
2023
Q1 		$2.41K Buy
150
+87
+138% +$1.61K ﹤0.01% 3713
2022
Q4 		$1.15K Sell
63
-18
-22% -$317 ﹤0.01% 3894
2022
Q3 		$2K Buy
81
+18
+29% +$367 ﹤0.01% 3811
2022
Q2 		$1K Hold
63
– – ﹤0.01% 3936
2022
Q1 		$1K Hold
63
– – ﹤0.01% 3927
2021
Q4 		$2K Hold
63
– – ﹤0.01% 3872
2021
Q3 		$1K Sell
63
-128
-67% -$2.68K ﹤0.01% 3964
2021
Q2 		$4K Buy
191
+77
+68% +$1.35K ﹤0.01% 3657
2021
Q1 		$2K Buy
114
+51
+81% +$790 ﹤0.01% 3686
2020
Q4 		$1K Buy
+63
New +$878 ﹤0.01% 3645

Other funds holding CRNX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JT
Jupiter Topco New York $245B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

US Bancorp's CRNX Position: Q2 2026 in Review

US Bancorp reduced its Crinetics Pharmaceuticals (CRNX) stake by 1.3% in Q2 2026, selling an estimated $3.49K and leaving 6,967 shares worth $261K. The position accounts for ﹤0.01% of the portfolio, ranked #1961.

US Bancorp first reported a position in CRNX in Q4 2020 and has held it in 23 quarters since. The position peaked at $587K in Q3 2024. 267 funds tracked by Wall St. Rank hold CRNX as of Q2 2026.

  • US Bancorp held 6,967 shares of Crinetics Pharmaceuticals worth $261K as of Q2 2026.
  • US Bancorp sold 94 Crinetics Pharmaceuticals shares in Q2 2026, an estimated $3.49K.
  • Crinetics Pharmaceuticals made up ﹤0.01% of US Bancorp's portfolio in Q2 2026, its #1961 holding.
  • US Bancorp first reported a position in Crinetics Pharmaceuticals in Q4 2020 and has held it in 23 quarters since.
  • US Bancorp's Crinetics Pharmaceuticals position peaked at $587K in Q3 2024.
  • 267 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q2 2026.

Based on US Bancorp's 13F filing for Q2 2026, filed 12 Aug 2026.